abstract |
The present invention relates to non-human animals that are deficient in the N-terminal domain of the IL-33 gene. Also, in particular, the use of said non-human animal as an in vivo model of inflammatory disease, with respect to screening methods for anti-inflammatory compounds and methods for evaluating and optimizing the pharmacological properties of a given anti-inflammatory compound Are also provided herein. |